相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Multidisciplinary Sciences
Bruno Pozzetto et al.
Summary: The study found that a heterologous vaccination regimen using ChAdOx1-S-nCoV-19 and BNT162b2 can provide better protection against SARS-CoV-2 infection with stronger neutralizing activity. This approach can activate memory B cells that recognize SARS-CoV-2, making it suitable for immunocompromised individuals.
Article
Immunology
Qian He et al.
Summary: Our study demonstrated that utilizing a heterologous prime-boost strategy with different combinations of COVID-19 vaccine candidates can enhance neutralizing antibody levels and T cell responses, providing new insights for vaccine development and application in controlling the SARS-CoV-2 pandemic.
EMERGING MICROBES & INFECTIONS
(2021)
Article
Medicine, General & Internal
Juan Manuel Carreno et al.
Summary: The study found that currently circulating viral variants, including Iota and Delta, show only minimal decreases in neutralization, while the Lambda sub-variant exhibits a significant reduction in neutralization, followed by Beta and Alpha (E484K). Overall, mRNA SARS-CoV-2 vaccines may still be effective against these viral variants, and receptor binding domain and spike binding antibody tests may retain specificity in the face of evolving SARS-CoV-2 diversity.
Article
Virology
Lin Cheng et al.
Summary: The emergence and rapid spread of the B.1.1.7 SARS-CoV-2 variant has raised global concern. The N501Y substitution in this variant raised concerns about its recognition by neutralizing antibodies. Most detected antibodies were unaffected by this substitution, although CB6's neutralizing and binding activities decreased, while BD-23's increased. These findings could be valuable for therapeutic antibody development.
Article
Biochemistry & Molecular Biology
Chang Liu et al.
Summary: Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.
Article
Cell Biology
Shiyu Sun et al.
Summary: By utilizing interferon-armed RBD to enhance antigen processing and cross-presentation, researchers have developed the I-P-R-F vaccine, which provides comprehensive protection with a single dose and elicits stronger immune responses than traditional RBD vaccines.
Article
Biochemistry & Molecular Biology
Joana Barros-Martins et al.
Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
John S. Tregoning et al.
Summary: The development and rollout of vaccines have brought hope for controlling the COVID-19 pandemic, with vaccines proving highly effective in preventing disease. However, challenges remain in ensuring equitable access to vaccines globally, as well as lessons to be learned for controlling pandemics in the future.
NATURE REVIEWS IMMUNOLOGY
(2021)
Letter
Infectious Diseases
Sonia Jangra et al.
Article
Medicine, General & Internal
Hong-Xing Pan et al.
Summary: This study reported the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults. The vaccine demonstrated good tolerability and induced robust immune responses in both phase 1 and phase 2 trials.
CHINESE MEDICAL JOURNAL
(2021)
Article
Biochemistry & Molecular Biology
Lianpan Dai et al.
Article
Multidisciplinary Sciences
Jingyun Yang et al.
